The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome
Open accessAbstract
Activation of the inflammasome generates the pro-inflammatory cytokines interleukin-1 beta and -18, which are important mediators of inflammation. Abnormal activation of the inflammasome leads to many inflammatory diseases, including gout, silicosis, neurodegeneration, and genetically inherited periodic fever syndromes. Therefore, identification of small molecule inhibitors that target the inflammasome is an important step toward developing effective therapeutics for the treatment of inflammation. Here, we show that the herbal NF-kappaB inhibitory compound parthenolide inhibits the activity of multiple inflammasomes in macrophages by directly inhibiting the protease activity of caspase-1. Additional investigations of other NF-kappaB inhibitors revealed that the synthetic I kappaB kinase-beta inhibitor Bay 11-7082 and structurally related vinyl sulfone compounds selectively inhibit NLRP3 inflammasome activity in macrophages independent of their inhibitory effect on NF-kappaB activity. In vitro assays of the effect of parthenolide and Bay 11-7082 on the ATPase activity of NLRP3 demonstrated that both compounds inhibit the ATPase activity of NLRP3, suggesting that the inhibitory effect of these compounds on inflammasome activity could be mediated in part through their effect on the ATPase activity of NLRP3. Our results thus elucidate the molecular mechanism for the therapeutic anti-inflammatory activity of parthenolide and identify vinyl sulfones as a new class of potential therapeutics that target the NLRP3 inflammasome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Pyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,183
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Self-citationBauernfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B. G., Fitzgerald, K. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901363 · Cited by 2,959
Self-citationThioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationThe Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
Fernandes-Alnemri, T., Yu, J.-W., Datta, P., Wu, J., & Alnemri, E. S. (2009) · Nature · doi:10.1038/nature07710 · Cited by 1,831
Self-citationHoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Cited by
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citationActivation and regulation of the inflammasomes
Latz, E., Xiao, T. S., & Stutz, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3452 · Cited by 2,884
Self-citationPyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., & Núñez, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.016 · Cited by 2,147
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
Self-citationRecent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1413-8 · Cited by 1,269
Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection
Doitsh, G., Galloway, N. L. K., Geng, X., Yang, Z., Monroe, K. M., Zepeda, O., Hunt, P. W., Hatano, H., Sowinski, S., Muñoz-Arias, I., et al. (2014) · Nature · doi:10.1038/nature12940 · Cited by 1,179
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
Hu, J. J., Liu, X., Xia, S., Zhang, Z., Zhang, Y., Zhao, J., Ruan, J., Luo, X., Lou, X., Bai, Y., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0669-6 · Cited by 1,145
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
He, H., Jiang, H., Chen, Y., Ye, J., Wang, A., Wang, C., Liu, Q., Liang, G., Deng, X., Jiang, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04947-6 · Cited by 827
Non-transcriptional Priming and Deubiquitination Regulate NLRP3 Inflammasome Activation
Juliana, C., Fernandes-Alnemri, T., Kang, S., Farias, A., Qin, F., & Alnemri, E. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407130 · Cited by 773
Self-citationNLRP3 and pyroptosis blockers for treating inflammatory diseases
Coll, R. C., Schroder, K., & Pelegrín, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.003 · Cited by 755
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., Wang, A., Tao, J., Wang, C., Liu, Q., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171419 · Cited by 748
The AIM2 inflammasome is critical for innate immunity to Francisella tularensis
Fernandes-Alnemri, T., Yu, J.-W., Juliana, C., Solorzano, L., Kang, S., Wu, J., Datta, P., McCormick, M., Huang, L., McDermott, E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1859 · Cited by 732
Self-citationDeubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity
Py, B. F., Kim, M.-S., Vakifahmetoglu-Norberg, H., & Yuan, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.11.009 · Cited by 715
Pharmacological Inhibitors of the NLRP3 Inflammasome
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02538 · Cited by 671
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
Hooftman, A., Angiari, S., Hester, S., Corcoran, S. E., Runtsch, M. C., Ling, C., Ruzek, M. C., Slivka, P. F., McGettrick, A. F., Banahan, K., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.07.016 · Cited by 609
Inflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593
“Small compounds that specifically target the inflammasom”
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam, T., Carta, S., Tengesdal, I., Nemkov, T., D’Alessandro, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716095115 · Cited by 574
Tranilast directly targets NLRP 3 to treat inflammasome‐driven diseases
Huang, Y., Jiang, H., Chen, Y., Wang, X., Yang, Y., Tao, J., Deng, X., Liang, G., Zhang, H., Jiang, W., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708689 · Cited by 507
Minutoli, L., Puzzolo, D., Rinaldi, M., Irrera, N., Marini, H., Arcoraci, V., Bitto, A., Crea, G., Pisani, A., Squadrito, F., et al. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2183026 · Cited by 505
Cooke, K. R., Luznik, L., Sarantopoulos, S., Hakim, F. T., Jagasia, M., Fowler, D. H., van den Brink, M. R. M., Hansen, J. A., Parkman, R., Miklos, D. B., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2016.09.023 · Cited by 472
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy
Shahzad, K., Bock, F., Dong, W., Wang, H., Kopf, S., Kohli, S., Al-Dabet, M. M., Ranjan, S., Wolter, J., Wacker, C., et al. (2015) · Kidney International · doi:10.1038/ki.2014.271 · Cited by 411
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock
Mao, K., Chen, S., Chen, M., Ma, Y., Wang, Y., Huang, B., He, Z., Zeng, Y., Hu, Y., Sun, S., et al. (2013) · Cell Research · doi:10.1038/cr.2013.6 · Cited by 395
Cell Volume Regulation Modulates NLRP3 Inflammasome Activation
Compan, V., Baroja-Mazo, A., López-Castejón, G., Gomez, A. I., Martínez, C. M., Angosto, D., Montero, M. T., Herranz, A. S., Bazán, E., Reimers, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.06.013 · Cited by 392
Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
Doyle, S., Ozaki, E., & Campbell, M. (2015) · Journal of Inflammation Research · doi:10.2147/jir.s51250 · Cited by 380
Karki, R., Man, S. M., & Kanneganti, T.-D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0269 · Cited by 377
Qiu, Z., Lei, S., Zhao, B., Wu, Y., Su, W., Liu, M., Meng, Q., Zhou, B., Leng, Y., & Xia, Z.-Y. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9743280 · Cited by 351
Pathogenesis of acute stroke and the role of inflammasomes
Fann, D. Y.-W., Lee, S.-Y., Manzanero, S., Chunduri, P., Sobey, C. G., & Arumugam, T. V. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.09.004 · Cited by 335
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
NLRP3 Inflammasome Mediates Chronic Mild Stress-Induced Depression in Mice via Neuroinflammation
Zhang, Y., Liu, L., Liu, Y.-Z., Shen, X.-L., Wu, T.-Y., Zhang, T., Wang, W., Wang, Y.-X., & Jiang, C.-L. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv006 · Cited by 325
NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain
Stutz, A., Kolbe, C.-C., Stahl, R., Horvath, G. L., Franklin, B. S., van Ray, O., Brinkschulte, R., Geyer, M., Meissner, F., & Latz, E. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160933 · Cited by 317
Self-citationExosome-like Nanoparticles from Ginger Rhizomes Inhibited NLRP3 Inflammasome Activation
Chen, X., Zhou, Y., & Yu, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00246 · Cited by 311
Self-citationFann, D. Y.-W., Lim, Y.-A., Cheng, Y.-L., Lok, K.-Z., Chunduri, P., Baik, S.-H., Drummond, G. R., Dheen, S. T., Sobey, C. G., Jo, D.-G., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0394-9 · Cited by 309
NLRP3 Inflammasome and Inflammatory Diseases
Wang, Z., Zhang, S., Xiao, Y., Zhang, W., Wu, S., Qin, T., Yue, Y., Qian, W., & Li, L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4063562 · Cited by 309
The role of inflammasomes in kidney disease
Komada, T., & Muruve, D. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0158-z · Cited by 304
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
Xu, W., Huang, Y., & Zhou, R. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01275-w · Cited by 295
Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications
Zeng, C., Wang, R., & Tan, H. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33568 · Cited by 283
He, Y., Varadarajan, S., Muñoz-Planillo, R., Burberry, A., Nakamura, Y., & Núñez, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.515080 · Cited by 268
Park, S., Juliana, C., Hong, S., Datta, P., Hwang, I., Fernandes-Alnemri, T., Yu, J.-W., & Alnemri, E. S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301170 · Cited by 266
Self-citationSpotlight on the NLRP3 inflammasome pathway
Groslambert, M., & Py, B. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s141220 · Cited by 263
Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis
Wong, K., & Jacobs Jr, W. R. (2011) · Cellular Microbiology · doi:10.1111/j.1462-5822.2011.01625.x · Cited by 209
HIV-1 tat primes and activates microglial NLRP3 inflammasome-mediated neuroinflammation.
Chivero, E. T., Guo, M.-L., Periyasamy, P., Liao, K., Callen, S. E., & Buch, S. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3045-16.2017 · Cited by 201
Lung inflammation caused by inhaled toxicants: A review
Wong, J., Magun, B., & Wood, L. (2016) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s106009 · Cited by 193
Gomez-Cabrera, M. C., Salvador-Pascual, A., Cabo, H., Ferrando, B., & Viña, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.006 · Cited by 172
The Role of the Inflammasome in Neurodegenerative Diseases
Piancone, F., La Rosa, F., Marventano, I., Saresella, M., & Clerici, M. (2021) · Molecules · doi:10.3390/molecules26040953 · Cited by 144
Principles of inflammasome priming and inhibition: implications for psychiatric disorders
Herman, F. J., & Pasinetti, G. M. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.010 · Cited by 115
Zhao, N., Li, C.-C., Di, B., & Xu, L.-L. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102515 · Cited by 103
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Zhang, X., Fan, C., Zhang, H., Zhao, Q., Liu, Y., Xu, C., Xie, Q., Wu, X., Yu, X., Zhang, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.103 · Cited by 93
Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of NLRP3 inflammasome
Bulugonda, R. K., kumar, K. A., Gangappa, D., Beeda, H., Philip, G. H., Muralidhara Rao, D., & Faisal, S. M. (2017) · Scientific Reports · doi:10.1038/srep42683 · Cited by 74
“The homogenate was centrifuged for 30 min at 10,000 rpm at 4 °C and the protein content in the supernatant was measured by Bradford method 9 .”
Transcriptome sequencing of microglial cells stimulated with TLR3 and TLR4 ligands
Das, A., Chai, J. C., Kim, S. H., Lee, Y. S., Park, K. S., Jung, K. H., & Chai, Y. G. (2015) · BMC Genomics · doi:10.1186/s12864-015-1728-5 · Cited by 64
NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity
Amin, S., Aktar, S., Rahman, M. M., & Chowdhury, M. M. H. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2021.104913 · Cited by 51
Therapeutic Role of Inflammasome Inhibitors in Neurodegenerative Disorders
Lahooti, B., Chhibber, T., Bagchi, S., Varahachalam, S. P., & Jayant, R. D. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.004 · Cited by 50
Metadata
- Authors
- Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J.-W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., & Alnemri, E. S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 285
- Issue
- 13
- Pages
- 9792-9802
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2057039052
- Cited by
- 610
- References
- 42
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.